Sompo Asset Management Co. Ltd. grew its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 11.2% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 63,593 shares of the company’s stock after acquiring an additional 6,410 shares during the period. Johnson & Johnson comprises approximately 2.1% of Sompo Asset Management Co. Ltd.’s holdings, making the stock its 10th largest position. Sompo Asset Management Co. Ltd.’s holdings in Johnson & Johnson were worth $9,857,000 as of its most recent SEC filing.
Other hedge funds have also recently modified their holdings of the company. Martin Investment Management LLC boosted its holdings in Johnson & Johnson by 0.4% in the 1st quarter. Martin Investment Management LLC now owns 45,870 shares of the company’s stock worth $7,110,000 after buying an additional 173 shares during the period. Roundview Capital LLC boosted its holdings in Johnson & Johnson by 2.8% in the 1st quarter. Roundview Capital LLC now owns 80,840 shares of the company’s stock worth $12,530,000 after buying an additional 2,164 shares during the period. Clearstead Advisors LLC boosted its holdings in Johnson & Johnson by 2.4% in the 1st quarter. Clearstead Advisors LLC now owns 61,617 shares of the company’s stock worth $9,551,000 after buying an additional 1,427 shares during the period. Lionsbridge Wealth Management LLC boosted its holdings in Johnson & Johnson by 1.1% in the 1st quarter. Lionsbridge Wealth Management LLC now owns 8,424 shares of the company’s stock worth $1,306,000 after buying an additional 90 shares during the period. Finally, SFE Investment Counsel boosted its holdings in Johnson & Johnson by 0.5% in the 1st quarter. SFE Investment Counsel now owns 17,324 shares of the company’s stock worth $2,859,000 after buying an additional 80 shares during the period. Institutional investors own 67.57% of the company’s stock.
Wall Street Analyst Weigh In
JNJ has been the topic of several research analyst reports. StockNews.com initiated coverage on shares of Johnson & Johnson in a research note on Thursday. They issued a “strong-buy” rating on the stock. Stifel Nicolaus boosted their price target on shares of Johnson & Johnson from $165.00 to $175.00 in a research note on Friday, July 21st. Barclays boosted their price target on shares of Johnson & Johnson from $171.00 to $175.00 and gave the stock an “equal weight” rating in a research note on Monday, July 24th. JPMorgan Chase & Co. upped their target price on shares of Johnson & Johnson from $175.00 to $180.00 and gave the company a “neutral” rating in a research report on Friday, July 21st. Finally, Morgan Stanley restated an “equal weight” rating and set a $187.00 target price on shares of Johnson & Johnson in a research report on Friday, July 21st. Eight investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $171.80.
Insiders Place Their Bets
In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 12,465 shares of the company’s stock in a transaction dated Monday, June 12th. The shares were sold at an average price of $160.00, for a total value of $1,994,400.00. Following the transaction, the executive vice president now directly owns 65,934 shares in the company, valued at approximately $10,549,440. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, EVP Kathryn E. Wengel sold 12,465 shares of the stock in a transaction that occurred on Monday, June 12th. The shares were sold at an average price of $160.00, for a total transaction of $1,994,400.00. Following the transaction, the executive vice president now directly owns 65,934 shares in the company, valued at $10,549,440. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider William Hait sold 14,698 shares of the stock in a transaction that occurred on Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the transaction, the insider now owns 87,747 shares in the company, valued at $15,092,484. The disclosure for this sale can be found here. Insiders have sold 47,163 shares of company stock worth $7,928,856 in the last three months. Corporate insiders own 0.20% of the company’s stock.
Johnson & Johnson Stock Performance
Johnson & Johnson stock opened at $172.55 on Friday. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.12 and a quick ratio of 0.88. Johnson & Johnson has a 1-year low of $150.11 and a 1-year high of $181.04. The firm has a market capitalization of $448.45 billion, a P/E ratio of 34.93, a price-to-earnings-growth ratio of 2.89 and a beta of 0.54. The company’s 50-day moving average is $166.30 and its 200 day moving average is $161.44.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its quarterly earnings data on Thursday, July 20th. The company reported $2.80 earnings per share for the quarter, topping analysts’ consensus estimates of $2.62 by $0.18. The company had revenue of $25.53 billion for the quarter, compared to analyst estimates of $24.63 billion. Johnson & Johnson had a net margin of 13.35% and a return on equity of 36.72%. The firm’s revenue for the quarter was up 6.3% on a year-over-year basis. During the same period in the prior year, the company posted $2.59 EPS. Research analysts forecast that Johnson & Johnson will post 10.75 EPS for the current year.
Johnson & Johnson Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Thursday, September 7th. Shareholders of record on Monday, August 28th will be paid a $1.19 dividend. The ex-dividend date of this dividend is Friday, August 25th. This represents a $4.76 dividend on an annualized basis and a yield of 2.76%. Johnson & Johnson’s dividend payout ratio is currently 96.36%.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Featured Stories
- Five stocks we like better than Johnson & Johnson
- What Are Defense Contractor Stocks? How to Invest in Defense
- 8 Best Artificial Intelligence Stocks Under $10
- Investing in Commodities: What Are They? How to Invest in Them
- What Ross Stores Earnings Say About The Saver Shopping Economy
- How to Invest in Communication Stocks
- 6 Largest Healthcare REITs to Buy and How to Invest
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
